Contenu connexe
Similaire à Dp change-control-system-1.01
Similaire à Dp change-control-system-1.01 (20)
Dp change-control-system-1.01
- 1. Quality Management
Documents & Templates
Change Control
• The applicant/change requester notifies the Change Control System Owner (Quality
Assurance) at the same time that a change proposal / request has been raised.
• The applicant/change requester ensures that a change is not implemented until the change
has been evaluated and approved by Quality Assurance.
• The applicant/change requester coordinates the implementation of an approved change
request.
• The applicant/change requester pro-actively follows up actions required to ensure the
completion and formal close out of the change request in a timely manner/following the
implementation target dates in section 3 on the attached change control form.
4.2 Area Experts / Accountable Area Leaders
Area Experts / Accountable Area Leaders must assess if the change request might impact their
areas. This assessment must be documented by the Area Experts / Accountable Area Leaders in
Section 2 on the attached change control form.
4.3 Quality Assurance
The Quality Assurance (QA) Department is the owner of the change control system and maintains
the Change Control register file. QA assigns individual numbers for each change request and
ensures that documented evidence exists for the assessment. Finally QA tracks the close out of
changes and communicates proposals, amendments, approvals, rejections and close outs to all
affected parties.
The Quality Assurance Department must perform the following assessments and approvals:
• Understands and agrees on the scope of the change prior to approving the request.
• Ensures changes are not duplicated and do not adversely impact other areas and other
changes.
• Take accountability that the impact of the change has been appropriately evaluated which
includes but in not limited to:
o Ensuring that regulatory compliance with all submitted and approved registrations
e.g. New Drug Applications (NDA), Manufacturing Authorization Applications (MAA),
Investigational New Drug Application (IND) and Clinical Trial Exemptions (CTX) is
not impacted.
o Ensuring that GMP/GLP conditions are maintained.
o Ensuring that documentation is clear and complete.
o Ensuring that appropriate reviews are complete.
o Ensuring that validation status is maintained, and if not appropriate re-validation
activities are initiated.
o Ensuring that personnel are appropriately trained and the training is documented
prior change implementation.
o Evaluating if stability program is impacted.
Document Type Document ID Version Status Page
SOP XX_WWW_ZZZ_YYYY 1.0 Approved 5/10
Copyright © by QMdocs 2010
Reproduction, photocopying, storage or transmission by magnetic or electronic means strictly prohibited by law. Neither the document
nor the information contained therein may be reproduced or disclosed without written consent of QMdocs.